Prostate Cancer - Pipeline Review, H2 2016

 


Get this Report



PayPal Verified Vendor

Rating

4.9 Star Rating for report Prostate Cancer - Pipeline Review, H2 2016
4.9 / 5 stars rating
Pages: 1699
Price: $2500.00

Some of our Clients

Some Research and Expert Clients

Abstract

 
Prostate cancer is a form of cancer that affects men and starts off in the prostate gland. Prostate cancer usually occurs in older men. Symptoms include trouble urinating, decreased force in the stream of urine, blood in the urine, pain in the lower back, hips or thighs, bone pain and erectile dysfunction. Predisposing factors include age, family history and obesity. Treatment includes surgery, chemotherapy and radiation therapy.  

Description

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Prostate Cancer - Pipeline Review, H2 2016, provides an overview of the Prostate Cancer (Oncology) pipeline landscape.

Prostate cancer is a form of cancer that affects men and starts off in the prostate gland. Prostate cancer usually occurs in older men. Symptoms include trouble urinating, decreased force in the stream of urine, blood in the urine, pain in the lower back, hips or thighs, bone pain and erectile dysfunction. Predisposing factors include age, family history and obesity. Treatment includes surgery, chemotherapy and radiation therapy.
 

Similar Reports

Other reports that may be of interest...

Report... 05ID-GBIHC429MRFrontier Pharma: Melanoma Therapeutics - Cytokine and Multiple T...Jan 2017
Report... 05IB-GMDHC8848IDBColon Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8854IDBLiver Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8858IDBGlioblastoma Multiforme (GBM) - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8917IDBHigh-Grade Glioma - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8891IDBWilms' Tumor (Nephroblastoma) - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8896IDBMerkel Cell Carcinoma - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8908IDBRecurrent Malignant Glioma - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8909IDBMetastatic Uveal Melanoma - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8862IDBPancreatic Cancer - Pipeline Review, H2 2016Dec 2016

Report Source Information

Supplied by: Research and Experts 
Date Published: 2016-12-21 

Report: Prostate Cancer - Pipeline Review, H2 2016

 

Contents

Table of Contents
Table of Contents 2
Introduction 14
Prostate Cancer Overview 15
Therapeutics Development 16
Prostate Cancer - Therapeutics under Development by Companies 18
Prostate Cancer - Therapeutics under Investigation by Universities/Institutes 41
Prostate Cancer - Pipeline Products Glance 46
Prostate Cancer - Products under Development by Companies 50
Prostate Cancer - Products under Investigation by Universities/Institutes 82
Prostate Cancer - Companies Involved in Therapeutics Development 89
Prostate Cancer - Therapeutics Assessment 370
Drug Profiles 404
Prostate Cancer - Dormant Projects 1571
Prostate Cancer - Discontinued Products 1619
Prostate Cancer - Product Development Milestones 1629
Appendix 1639
 

List of Tables


List of Tables
Number of Products under Development for Prostate Cancer, H2 2016 75
Number of Products under Development for Prostate Cancer - Comparative Analysis, H2 2016 76
Number of Products under Development by Companies, H2 2016 77
Number of Products under Development by Companies, H2 2016 (Contd..1) 78
Number of Products under Development by Companies, H2 2016 (Contd..2) 79
Number of Products under Development by Companies, H2 2016 (Contd..3) 80
Number of Products under Development by Companies, H2 2016 (Contd..4) 81
Number of Products under Development by Companies, H2 2016 (Contd..5) 82
Number of Products under Development by Companies, H2 2016 (Contd..6) 83
Number of Products under Development by Companies, H2 2016 (Contd..7) 84
Number of Products under Development by Companies, H2 2016 (Contd..8) 85
Number of Products under Development by Companies, H2 2016 (Contd..9) 86
Number of Products under Development by Companies, H2 2016 (Contd..10) 87
Number of Products under Development by Companies, H2 2016 (Contd..11) 88
Number of Products under Development by Companies, H2 2016 (Contd..12) 89
Number of Products under Development by Companies, H2 2016 (Contd..13) 90
Number of Products under Development by Companies, H2 2016 (Contd..14) 91
Number of Products under Development by Companies, H2 2016 (Contd..15) 92
Number of Products under Development by Companies, H2 2016 (Contd..16) 93
Number of Products under Development by Companies, H2 2016 (Contd..17) 94
Number of Products under Development by Companies, H2 2016 (Contd..18) 95
Number of Products under Development by Companies, H2 2016 (Contd..19) 96
Number of Products under Development by Companies, H2 2016 (Contd..20) 97
Number of Products under Development by Companies, H2 2016 (Contd..21) 98
Number of Products under Development by Companies, H2 2016 (Contd..22) 99
Number of Products under Investigation by Universities/Institutes, H2 2016 100
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 101
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 102
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 103
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..4) 104
Comparative Analysis by Late Stage Development, H2 2016 105
Comparative Analysis by Clinical Stage Development, H2 2016 106
Comparative Analysis by Early Stage Development, H2 2016 107
Comparative Analysis by Unknown Stage Development, H2 2016 108
Products under Development by Companies, H2 2016 109
Products under Development by Companies, H2 2016 (Contd..1) 110
Products under Development by Companies, H2 2016 (Contd..2) 111
Products under Development by Companies, H2 2016 (Contd..3) 112
Products under Development by Companies, H2 2016 (Contd..4) 113
Products under Development by Companies, H2 2016 (Contd..5) 114
Products under Development by Companies, H2 2016 (Contd..6) 115
Products under Development by Companies, H2 2016 (Contd..7) 116
Products under Development by Companies, H2 2016 (Contd..8) 117
Products under Development by Companies, H2 2016 (Contd..9) 118
Products under Development by Companies, H2 2016 (Contd..10) 119
Products under Development by Companies, H2 2016 (Contd..11) 120
Products under Development by Companies, H2 2016 (Contd..12) 121
Products under Development by Companies, H2 2016 (Contd..13) 122
Products under Development by Companies, H2 2016 (Contd..14) 123
Products under Development by Companies, H2 2016 (Contd..15) 124
Products under Development by Companies, H2 2016 (Contd..16) 125
Products under Development by Companies, H2 2016 (Contd..17) 126
Products under Development by Companies, H2 2016 (Contd..18) 127
Products under Development by Companies, H2 2016 (Contd..19) 128
Products under Development by Companies, H2 2016 (Contd..20) 129
Products under Development by Companies, H2 2016 (Contd..21) 130
Products under Development by Companies, H2 2016 (Contd..22) 131
Products under Development by Companies, H2 2016 (Contd..23) 132
Products under Development by Companies, H2 2016 (Contd..24) 133
Products under Development by Companies, H2 2016 (Contd..25) 134
Products under Development by Companies, H2 2016 (Contd..26) 135
Products under Development by Companies, H2 2016 (Contd..27) 136
Products under Development by Companies, H2 2016 (Contd..28) 137
Products under Development by Companies, H2 2016 (Contd..29) 138
Products under Development by Companies, H2 2016 (Contd..30) 139
Products under Development by Companies, H2 2016 (Contd..31) 140
Products under Investigation by Universities/Institutes, H2 2016 141
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 142
Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 143
Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 144
Products under Investigation by Universities/Institutes, H2 2016 (Contd..4) 145
Products under Investigation by Universities/Institutes, H2 2016 (Contd..5) 146
Products under Investigation by Universities/Institutes, H2 2016 (Contd..6) 147
Prostate Cancer - Pipeline by 4SC AG, H2 2016 148
Prostate Cancer - Pipeline by AB Science SA, H2 2016 149
Prostate Cancer - Pipeline by AbbVie Inc, H2 2016 150
Prostate Cancer - Pipeline by Actinium Pharmaceuticals Inc, H2 2016 151
Prostate Cancer - Pipeline by Adamis Pharmaceuticals Corp, H2 2016 152
Prostate Cancer - Pipeline by ADC Therapeutics Sarl, H2 2016 153
Prostate Cancer - Pipeline by Addex Therapeutics Ltd, H2 2016 154
Prostate Cancer - Pipeline by Aduro BioTech Inc, H2 2016 155
Prostate Cancer - Pipeline by Advanced Accelerator Applications SA, H2 2016 156
Prostate Cancer - Pipeline by Advanced Cancer Therapeutics, H2 2016 157
Prostate Cancer - Pipeline by Advantagene Inc, H2 2016 158
Prostate Cancer - Pipeline by Advaxis Inc, H2 2016 159
Prostate Cancer - Pipeline by Aeglea BioTherapeutics Inc, H2 2016 160
Prostate Cancer - Pipeline by Aeolus Pharmaceuticals Inc, H2 2016 161
Prostate Cancer - Pipeline by Aeterna Zentaris Inc, H2 2016 162
Prostate Cancer - Pipeline by Aileron Therapeutics Inc, H2 2016 163
Prostate Cancer - Pipeline by Akshaya Bio Inc, H2 2016 164
Prostate Cancer - Pipeline by Alchemia Ltd, H2 2016 165
Prostate Cancer - Pipeline by Alethia Biotherapeutics Inc, H2 2016 166
Prostate Cancer - Pipeline by Alissa Pharma, H2 2016 167
Prostate Cancer - Pipeline by Almac Discovery Ltd, H2 2016 168
Prostate Cancer - Pipeline by Ambrx Inc, H2 2016 169
Prostate Cancer - Pipeline by American Gene Technologies International Inc, H2 2016 170
Prostate Cancer - Pipeline by Amgen Inc, H2 2016 171
Prostate Cancer - Pipeline by Anavex Life Sciences Corp, H2 2016 172
Prostate Cancer - Pipeline by AndroScience Corp, H2 2016 173
Prostate Cancer - Pipeline by AnGes MG Inc, H2 2016 174
Prostate Cancer - Pipeline by AntiCancer Inc, H2 2016 175
Prostate Cancer - Pipeline by Antigen Express Inc, H2 2016 176
Prostate Cancer - Pipeline by Antisense Therapeutics Ltd, H2 2016 177
Prostate Cancer - Pipeline by Apac Biotech Pvt Ltd, H2 2016 178
Prostate Cancer - Pipeline by Apcure SAS, H2 2016 179
Prostate Cancer - Pipeline by Aphios Corp, H2 2016 180
Prostate Cancer - Pipeline by APIM Therapeutics AS, H2 2016 181
Prostate Cancer - Pipeline by Aptevo Therapeutics Inc, H2 2016 182
Prostate Cancer - Pipeline by Aptose Biosciences Inc, H2 2016 183
Prostate Cancer - Pipeline by ARMO Biosciences Inc, H2 2016 184
Prostate Cancer - Pipeline by Armour Therapeutics Inc, H2 2016 185
Prostate Cancer - Pipeline by Arno Therapeutics Inc, H2 2016 186
Prostate Cancer - Pipeline by ArQule Inc, H2 2016 187
Prostate Cancer - Pipeline by Arrien Pharmaceuticals LLC, H2 2016 188
Prostate Cancer - Pipeline by Arrowhead Pharmaceuticals Inc, H2 2016 189
Prostate Cancer - Pipeline by Arvinas Inc, H2 2016 190
Prostate Cancer - Pipeline by Asana BioSciences LLC, H2 2016 191
Prostate Cancer - Pipeline by Astellas Pharma Inc, H2 2016 192
Prostate Cancer - Pipeline by Asterias Biotherapeutics Inc, H2 2016 193
Prostate Cancer - Pipeline by AstraZeneca Plc, H2 2016 194
Prostate Cancer - Pipeline by ATLAB Pharma SAS, H2 2016 195
Prostate Cancer - Pipeline by Aura Biosciences Inc, H2 2016 196
Prostate Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H2 2016 197
Prostate Cancer - Pipeline by Avipep Pty Ltd, H2 2016 198
Prostate Cancer - Pipeline by Azaya Therapeutics Inc, H2 2016 199
Prostate Cancer - Pipeline by Bavarian Nordic A/S, H2 2016 200
Prostate Cancer - Pipeline by Bayer AG, H2 2016 201
Prostate Cancer - Pipeline by BeiGene Ltd, H2 2016 202
Prostate Cancer - Pipeline by Bexion Pharmaceuticals LLC, H2 2016 203
Prostate Cancer - Pipeline by BHR Pharma LLC, H2 2016 204
Prostate Cancer - Pipeline by Bio-Cancer Treatment International Ltd, H2 2016 205
Prostate Cancer - Pipeline by Biotest AG, H2 2016 206
Prostate Cancer - Pipeline by Biscayne Pharmaceuticals Inc, H2 2016 207
Prostate Cancer - Pipeline by Blirt SA, H2 2016 208
Prostate Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016 209
Prostate Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016 210
Prostate Cancer - Pipeline by Camurus AB, H2 2016 211
Prostate Cancer - Pipeline by Can-Fite BioPharma Ltd, H2 2016 212
Prostate Cancer - Pipeline by CEL-SCI Corp, H2 2016 213
Prostate Cancer - Pipeline by Celgene Corp, H2 2016 214
Prostate Cancer - Pipeline by CellCentric Ltd, H2 2016 215
Prostate Cancer - Pipeline by Cellceutix Corp, H2 2016 216
Prostate Cancer - Pipeline by Celldex Therapeutics Inc, H2 2016 217
Prostate Cancer - Pipeline by Cellectar Biosciences Inc, H2 2016 218
Prostate Cancer - Pipeline by Cellmid Ltd, H2 2016 219
Prostate Cancer - Pipeline by Celprogen Inc, H2 2016 220
Prostate Cancer - Pipeline by Chamaeleo Pharma NV, H2 2016 221
Prostate Cancer - Pipeline by Chiome Bioscience Inc, H2 2016 222
Prostate Cancer - Pipeline by Clovis Oncology Inc, H2 2016 223
Prostate Cancer - Pipeline by CohBar Inc, H2 2016 224
Prostate Cancer - Pipeline by Colby Pharmaceutical Company, H2 2016 225
Prostate Cancer - Pipeline by Corcept Therapeutics Inc, H2 2016 226
Prostate Cancer - Pipeline by Corvus Pharmaceuticals Inc, H2 2016 227
Prostate Cancer - Pipeline by Crescendo Biologics Ltd, H2 2016 228
Prostate Cancer - Pipeline by Curevac AG, H2 2016 229
Prostate Cancer - Pipeline by CytoVac A/S, H2 2016 230
Prostate Cancer - Pipeline by CZ BioMed Corp, H2 2016 231
Prostate Cancer - Pipeline by Deciphera Pharmaceuticals LLC, H2 2016 232
Prostate Cancer - Pipeline by DEKK-TEC Inc, H2 2016 233
Prostate Cancer - Pipeline by DexTech Medical AB, H2 2016 234
Prostate Cancer - Pipeline by Diffusion Pharmaceuticals Inc, H2 2016 235
Prostate Cancer - Pipeline by DNJ Pharma Inc, H2 2016 236
Prostate Cancer - Pipeline by Dongkook Pharmaceutical Co Ltd, H2 2016 237
Prostate Cancer - Pipeline by DormaTarg Inc, H2 2016 238
Prostate Cancer - Pipeline by Eisai Co Ltd, H2 2016 239
Prostate Cancer - Pipeline by Eli Lilly and Company, H2 2016 240
Prostate Cancer - Pipeline by Enceladus Pharmaceuticals BV, H2 2016 241
Prostate Cancer - Pipeline by EndoCeutics Inc, H2 2016 242
Prostate Cancer - Pipeline by Endocyte Inc, H2 2016 243
Prostate Cancer - Pipeline by EntreChem SL, H2 2016 244
Prostate Cancer - Pipeline by EOS Biosciences Inc, H2 2016 245
Prostate Cancer - Pipeline by Errant Gene Therapeutics LLC, H2 2016 246
Prostate Cancer - Pipeline by Esperance Pharmaceuticals Inc, H2 2016 247
Prostate Cancer - Pipeline by ESSA Pharma Inc, H2 2016 248
Prostate Cancer - Pipeline by Eureka Therapeutics Inc, H2 2016 249
Prostate Cancer - Pipeline by Evgen Pharma Plc, H2 2016 250
Prostate Cancer - Pipeline by Exonate Ltd, H2 2016 251
Prostate Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 252
Prostate Cancer - Pipeline by Ferring International Center SA, H2 2016 253
Prostate Cancer - Pipeline by Foresee Pharmaceuticals LLC, H2 2016 254
Prostate Cancer - Pipeline by Fountain Biopharma Inc, H2 2016 255
Prostate Cancer - Pipeline by Fujifilm Corp, H2 2016 256
Prostate Cancer - Pipeline by G1 Therapeutics Inc, H2 2016 257
Prostate Cancer - Pipeline by Galectin Therapeutics Inc, H2 2016 258
Prostate Cancer - Pipeline by Genelux Corp, H2 2016 259
Prostate Cancer - Pipeline by Genentech Inc, H2 2016 260
Prostate Cancer - Pipeline by GeneSegues Inc, H2 2016 261
Prostate Cancer - Pipeline by Genmab A/S, H2 2016 262
Prostate Cancer - Pipeline by Gilead Sciences Inc, H2 2016 263
Prostate Cancer - Pipeline by Glactone Pharma AB, H2 2016 264
Prostate Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016 265
Prostate Cancer - Pipeline by GlycoMimetics Inc, H2 2016 266
Prostate Cancer - Pipeline by GP Pharm SA, H2 2016 267
Prostate Cancer - Pipeline by GTx Inc, H2 2016 268
Prostate Cancer - Pipeline by Hadasit Medical Research Services & Development Ltd, H2 2016 269
Prostate Cancer - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2016 270
Prostate Cancer - Pipeline by Health Ever Bio-Tech Co Ltd, H2 2016 271
Prostate Cancer - Pipeline by Hybrigenics SA, H2 2016 272
Prostate Cancer - Pipeline by IC-MedTech Inc, H2 2016 273
Prostate Cancer - Pipeline by Ideaya Biosciences Inc, H2 2016 274
Prostate Cancer - Pipeline by IGF Oncology LLC, H2 2016 275
Prostate Cancer - Pipeline by Ignyta Inc, H2 2016 276
Prostate Cancer - Pipeline by Ildong Pharmaceutical Co Ltd, H2 2016 277
Prostate Cancer - Pipeline by Immune Pharmaceuticals Inc, H2 2016 278
Prostate Cancer - Pipeline by Immuneed AB, H2 2016 279
Prostate Cancer - Pipeline by Immunocore Ltd, H2 2016 280
Prostate Cancer - Pipeline by ImmunoFrontier Inc, H2 2016 281
Prostate Cancer - Pipeline by Immunomedics Inc, H2 2016 282
Prostate Cancer - Pipeline by Immupharma Plc, H2 2016 283
Prostate Cancer - Pipeline by Incanthera Ltd, H2 2016 284
Prostate Cancer - Pipeline by Incuron LLC, H2 2016 285
Prostate Cancer - Pipeline by Inflection Biosciences Ltd, H2 2016 286
Prostate Cancer - Pipeline by Innate Immunotherapeutics Ltd, H2 2016 287
 

List of Figures

List of Figures
Number of Products under Development for Prostate Cancer, H2 2016 75
Number of Products under Development for Prostate Cancer - Comparative Analysis, H2 2016 76
Number of Products under Development by Companies, H2 2016 77
Number of Products under Investigation by Universities/Institutes, H2 2016 100
Comparative Analysis by Late Stage Development, H2 2016 105
Comparative Analysis by Clinical Stage Development, H2 2016 106
Comparative Analysis by Early Stage Products, H2 2016 107
Assessment by Monotherapy Products, H2 2016 429
Assessment by Combination Products, H2 2016 430
Number of Products by Top 10 Targets, H2 2016 431
Number of Products by Stage and Top 10 Targets, H2 2016 431
Number of Products by Top 10 Mechanism of Actions, H2 2016 445
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 445
Number of Products by Top 10 Routes of Administration, H2 2016 459
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 459
Number of Products by Top 10 Molecule Types, H2 2016 461
Number of Products by Stage and Top 10 Molecule Types, H2 2016 461
 

Scope


- The pipeline guide provides a snapshot of the global therapeutic landscape of Prostate Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Prostate Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Prostate Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Prostate Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Prostate Cancer (Oncology)

 

Highlights

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Prostate Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Prostate Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Prostate Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Prostate Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 14, 91, 98, 4, 231, 32 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 12, 10, 58 and 23 molecules, respectively.

Prostate Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

 

Classification

Language Code: EN 
Region: Global 
Report Type: Market Report 
Industry: Life Sciences 
Sector: Oncology 
Pages: 1699 

Companies Featured

4SC AG AB Science SA AbbVie Inc Actinium Pharmaceuticals Inc Adamis Pharmaceuticals Corp ADC Therapeutics Sarl Addex Therapeutics Ltd Aduro BioTech Inc Advanced Accelerator Applications SA Advanced Cancer Therapeutics Advantagene Inc Advaxis Inc Aeglea BioTherapeutics Inc Aeolus Pharmaceuticals Inc Aeterna Zentaris Inc Aileron Therapeutics Inc Akshaya Bio Inc Alchemia Ltd Alethia Biotherapeutics Inc Alissa Pharma Almac Discovery Ltd Ambrx Inc American Gene Technologies International Inc Amgen Inc Anavex Life Sciences Corp AndroScience Corp AnGes MG Inc AntiCancer Inc Antigen Express Inc Antisense Therapeutics Ltd Apac Biotech Pvt Ltd Apcure SAS Aphios Corp APIM Therapeutics AS Aptevo Therapeutics Inc Aptose Biosciences Inc ARMO Biosciences Inc Armour Therapeutics Inc Arno Therapeutics Inc ArQule Inc Arrien Pharmaceuticals LLC Arrowhead Pharmaceuticals Inc Arvinas Inc Asana BioSciences LLC Astellas Pharma Inc Asterias Biotherapeutics Inc AstraZeneca Plc ATLAB Pharma SAS Aura Biosciences Inc Aurigene Discovery Technologies Ltd Avipep Pty Ltd Azaya Therapeutics Inc Bavarian Nordic A/S Bayer AG BeiGene Ltd Bexion Pharmaceuticals LLC BHR Pharma LLC Bio-Cancer Treatment International Ltd Biotest AG Biscayne Pharmaceuticals Inc Blirt SA Boehringer Ingelheim GmbH Bristol-Myers Squibb Company Camurus AB Can-Fite BioPharma Ltd CEL-SCI Corp Celgene Corp CellCentric Ltd Cellceutix Corp Celldex Therapeutics Inc Cellectar Biosciences Inc Cellmid Ltd Celprogen Inc Chamaeleo Pharma NV Chiome Bioscience Inc Clovis Oncology Inc CohBar Inc Colby Pharmaceutical Company Corcept Therapeutics Inc Corvus Pharmaceuticals Inc Crescendo Biologics Ltd Curevac AG CytoVac A/S CZ BioMed Corp Deciphera Pharmaceuticals LLC DEKK-TEC Inc DexTech Medical AB Diffusion Pharmaceuticals Inc DNJ Pharma Inc Dongkook Pharmaceutical Co Ltd DormaTarg Inc Eisai Co Ltd Eli Lilly and Company Enceladus Pharmaceuticals BV EndoCeutics Inc Endocyte Inc EntreChem SL EOS Biosciences Inc Errant Gene Therapeutics LLC Esperance Pharmaceuticals Inc ESSA Pharma Inc Eureka Therapeutics Inc Evgen Pharma Plc Exonate Ltd F. Hoffmann-La Roche Ltd Ferring International Center SA Foresee Pharmaceuticals LLC Fountain Biopharma Inc Fujifilm Corp G1 Therapeutics Inc Galectin Therapeutics Inc Genelux Corp Genentech Inc GeneSegues Inc Genmab A/S Gilead Sciences Inc Glactone Pharma AB GlaxoSmithKline Plc GlycoMimetics Inc GP Pharm SA GTx Inc Hadasit Medical Research Services & Development Ltd Hanmi Pharmaceuticals Co Ltd Health Ever Bio-Tech Co Ltd Hybrigenics SA IC-MedTech Inc Ideaya Biosciences Inc IGF Oncology LLC Ignyta Inc Ildong Pharmaceutical Co Ltd Immune Pharmaceuticals Inc Immuneed AB Immunocore Ltd ImmunoFrontier Inc Immunomedics Inc Immupharma Plc Incanthera Ltd Incuron LLC Inflection Biosciences Ltd Innate Immunotherapeutics Ltd Inovio Pharmaceuticals Inc Inspyr Therapeutics Inc Intech Biopharm Ltd Interceptin Io Therapeutics Inc Ionis Pharmaceuticals Inc Ipsen SA Jiangsu Hengrui Medicine Co Ltd Johnson & Johnson Jyant Technologies Inc Kaken Pharmaceutical Co Ltd KaloBios Pharmaceuticals Inc Karyopharm Therapeutics Inc Kite Pharma Inc Komipharm International Co Ltd Kura Oncology Inc Kyowa Hakko Kirin Co Ltd Lidds AB Luye Pharma Group Ltd MacroGenics Inc Mallinckrodt Plc Mateon Therapeutics Inc MaxiVAX SA Meabco A/S Mebiopharm Co Ltd Med Discovery SA MediaPharma srl MediGene AG MedImmune LLC Mediolanum farmaceutici SpA Medivation Inc MEI Pharma Inc Merck & Co Inc Merck KGaA Microlin Bio, Inc. Millennium Pharmaceuticals Inc Minerva Biotechnologies Corp Mithra Pharmaceuticals SA MolMed SpA Monopar Therapeutics LLC Morphotek Inc NewLink Genetics Corp NormOxys Inc Novartis AG Novogen Ltd Nymox Pharmaceutical Corp Oasmia Pharmaceutical AB Omeros Corp Omnitura Therapeutics Inc OncBioMune Pharmaceuticals Inc Oncodrone BV Oncogenex Pharmaceuticals Inc Oncolix Inc OncoMax OncoNOx ApS OncoTartis Inc OncoTherapy Science Inc Oncovir Inc Oncternal Therapeutics Inc Oneness Biotech Co Ltd Ono Pharmaceutical Co Ltd ORCA Therapeutics BV Oribase Pharma Oric Pharmaceuticals Inc Orion Oyj Orphagen Pharmaceuticals Inc Oxford BioMedica Plc Panacela Labs Inc Patrys Ltd PDS Biotechnology Corp Peptron Inc PepVax Inc Pfizer Inc Pharmedartis GmbH Pharmicell Co Ltd Pharminox Ltd Philogen SpA Polaris Pharmaceuticals Inc Polyplus-Transfection SA Prima BioMed Ltd Progenics Pharmaceuticals Inc Provectus Biopharmaceuticals Inc Provenance Biopharmaceuticals Corp PSites Pharma GmbH RedHill Biopharma Ltd Regulaxis SAS Rigontec GmbH Sanofi Selexel Sarl Senhwa Biosciences Inc Serometrix LLC Shenogen Pharma Group Ltd Shire Plc Sophiris Bio Inc Soricimed Biopharma Inc Sorrento Therapeutics Inc Sotio as Stemline Therapeutics Inc Strides Shasun Ltd Supratek Pharma Inc SyntheX Inc TaiGen Biotechnology Co Ltd Taiho Pharmaceutical Co Ltd Taiwan Liposome Company Ltd Takeda Pharmaceutical Company Ltd Takis Srl Targovax ASA Terpenoid Therapeutics Inc Tesaro Inc Teva Pharmaceutical Industries Ltd Theravectys SA Threshold Pharmaceuticals Inc Tiltan Pharma Ltd Tokai Pharmaceuticals Inc TRACON Pharmaceuticals Inc TREAT U SA Triphase Accelerator Corp TVAX Biomedical Inc Tyme Technologies Inc TyrNovo Ltd UbiVac LLC Ultimovacs AS Vaccibody AS ValiRx Plc Vasgen Ltd Vault Pharma Inc Vaxeal Holding SA Vaxon Biotech Vicore Pharma AB Vicus Therapeutics LLC Viralytics Ltd ViraTherapeutics GmbH VLP Therapeutics LLC Wilex AG WntResearch AB Xencor Inc Yungjin Pharm Co Ltd Zenith Capital Corp Zensun (Shanghai) Sci & Tech Co Ltd

 

Reasons to buy this report


- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Prostate Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Prostate Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 

Similar Reports

Other reports that may be of interest...

Report... 05ID-GBIHC429MRFrontier Pharma: Melanoma Therapeutics - Cytokine and Multiple T...Jan 2017
Report... 05IB-GMDHC8848IDBColon Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8854IDBLiver Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8858IDBGlioblastoma Multiforme (GBM) - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8917IDBHigh-Grade Glioma - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8891IDBWilms' Tumor (Nephroblastoma) - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8896IDBMerkel Cell Carcinoma - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8908IDBRecurrent Malignant Glioma - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8909IDBMetastatic Uveal Melanoma - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8862IDBPancreatic Cancer - Pipeline Review, H2 2016Dec 2016

Prostate Cancer - Pipeline Review, H2 2016

Report 05IB-GMDHC8860IDB has a rating of 98 percent
Figure of merit assessment for report 05IB-GMDHC8860IDB

Relevance Rating

The Research and Experts relevance ranting consists of a set of figure of merit (FOM) values that are provided as an indication of the value of the report in the current economic environment.

These FOM values cannot take into account the reason for the clients interest in a report and therefore the client should view these FOM values only as a visual guide. The FOM scores are based on

market interest - how often the report is viewed or purchased,
elapsed time - time since the report was published,
report detail - amount of detail in the report (pages, figures, images, comments etc.) and
price - the price of the report.


Regional Information

Taxonomy

Branch ID: 1591

Taxonomy Location

The taxonomy on the left shows the ancestors of the Global node. This provides an insight into parent categories that may provide reports or articles that may compliment this report. The number in brackets after the node name indicates the number of reports that Research and Experts currently have in the parent category.

Clicking on a parent category will present the list of reports in the parent node in a separate window.

Global

The global economy is the economy of all the world's countries. The total world population now stands at over 7 billion and the global unemployment rate is 9% with approximately half the world's population paid less than $2 a day. 

The global economy is picking up again after five years of uncertaintity and slow economic growth. The IMF is predicting global growth of 3.7% in 2014 rising to 3.9% in 2015. However, much uncertainity remains. Low inflation in developed economies means that these economies take longer to deal with debt burdens and are at increases risk of deflation. 

The second half of 2013 saw growth in the US and European economies (particularly UK, Germany and France).  

Growth in the US has been helped by cheaper energy from fracking , renewables and more oil and gas exploration. This cheaper energy is bring manufacturing jobs back to the US and helping to boost domestic demand. Recent winter weather conditions have hampered growth in the construction sector and have slowed demand in the construction equipment sector which saw exports drop by 25% in 2013. Growth should pick up in this sector with continued federal investment in infrastructure, new residential house builds and refurbishment and the energy boom.

In Europe growth is expected to be uneven with growth being slow in stressed economies such as Portugal and Greece but confidence picking up in UK, Ireland and even Spain showing some improvement.

Developing economies such as China and India will continue to have strong growth in 2014 and 2015. China has benefitted from increased investment with the Chinese govenment now focused on quality growth of 7.5% in 2014. India which is less reliant on exports expects growth of 5.4% in 2014 and 6.4% in 2015.

Much uncertainity still remains in the global economy with greater optimism needed to stabilise growth.

Links

World Bank

IMF (International Monetary Fund)

 

 

Zones

Regional zones

 

Country

Countries

 

Industry Sector Information

Taxonomy

Branch ID: 7174

Taxonomy Location

The taxonomy on the left shows the ancestors of the Oncology node. This provides an insight into parent categories that may provide reports or articles that may compliment this report. The number in brackets after the node name indicates the number of reports that Research and Experts currently have in the parent category.

Clicking on a parent category will present the list of reports in the parent node in a separate window.

Oncology

Oncology

 

Healthcare

The healthcare industry is changing rapidly due to changes in legislation (US Affordable Healthcare Act),  advances in IT and more pressures on governments and healthcare providers due to rising costs. 

According to a recent report by the OECD healthcare spending has fallen in one third of OECD member states due to the credit crunch and members are facing up to the challenge of providing greater care with fewer resources. Spending on healthcare has increased in Japan, Israel and Korea while it has dropped dramatically in Greece and Ireland.

Useful Links

World Health Organisation 

American Healthcare Association

The British Healthcare Business Intelligence Association

OECD, Health Policies and Data

Healthcare

Life Sciences

The Life Sciences industry includes biotechnology, healthcare, pharmaceuticals, medical devices and diagnostics. The industry is dominated by US companies requiring considerable investment in research and development to stay competitive.  While US companies dominate this space, competition is emerging from smaller companies in Europe and Asia. 

Companies trying to stay competitive or enter new markets in life sciences consult our reports. For example, Plimsoll, in their recent review of global antibiotic manufacturers have reviewed 150 of the largest manufacturers including analysis of  ANTIBIOTICE SA, BAYER HEALTHCARE MANUFACTURING SRL and CIPLA LTD. 

Our reports are a requirement for companies looking for the best competitive intelligence in the life sciences sector providing information on market size, rankings, best trading partners and financial analysis. 

Useful Links

Analytical Life Sciences and Diagnostics Association

German Life Sciences Association

 

Life Sciences

Industry

Industries

 

 

Buy: Prostate Cancer - Pipeline Review, H2 2016

 

Item Code: 05IB-GMDHC8860IDB

 
Licence: Single User
Price: $2500.00
 
VAT: 0.0% 
Total: $2500.00 

Feedback

Return to Research and Experts

Page created and rendered - Cache updated [2.01996s]

--